Researchers at Shanghai Jiao Tong University School of Medicine, China, have discovered that shutting down part of the innate immune system increases anti-tumor activity.
Anticancer treatment strategies increasingly seek to raise reactive oxygen species (ROS) levels, cause macromolecular damage, and kill cancer cells. Electromagnetic fields can elevate intracellular reactive oxygen species ...
Researchers at Memorial Sloan Kettering Cancer Center, New York, have concluded their phase 2 trial of chemotherapy in combination with the drugs nivolumab, and regorafenib.
Despite decades of research and tens of billions of dollars for research and treatments worldwide, the battle against cancer continues.
New insights into a population of tumor-infiltrating T cells may ultimately allow doctors to predict how patients will respond to checkpoint blockade immunotherapy, a form of cancer treatment with advantages that doctors ...
New research that is examining the "tumor microenvironment" reveals not only how macrophages can become extraordinary turncoats but also how they can actively support tumor growth and metastatic progression in certain forms ...
(Medical Xpress)—A team of researchers working at the Albert Einstein College of Medicine in the U.S. has found evidence that suggests administering chemotherapy to breast cancer patients prior to surgery can put them at ...
(Medical Xpress)—Medical research over the last decade has revealed the effects of the gut microbiome across a range of health markers including inflammation, immune response, metabolic function and weight. There is a corresponding ...
Like alien invaders in a sci-fi movie, pancreatic cancer cells quickly adapt to the weapons used against them and find ways to survive, even in the harshest of conditions.
Apr 4, 2024
0
20
Using novel machine learning tools developed at Stanford Medicine, researchers have mapped three distinct cellular configurations that correspond to clinical outcomes for patients with a rare, difficult-to-treat cancer called ...
Mar 27, 2024
0
28
